Bob Kramer, Emergent BioSolutions CEO (Emergent)

Woes con­tin­ue pil­ing up for Emer­gent as man­u­fac­tur­er faces in­vestor re­volt, in­sid­er trad­ing al­le­ga­tions

Emer­gent BioSo­lu­tions’ trou­bles have on­ly deep­ened since the New York Times re­port­ed in late March the CD­MO had mixed up Covid-19 vac­cine in­gre­di­ents from J&J and As­traZeneca. Adding to its list of woes, the Mary­land com­pa­ny is now fac­ing an in­vestor re­volt, too.

At least four share­hold­ers have filed law­suits against Emer­gent in the last few months, with the lat­est com­ing from a po­lice pen­sion fund in Chica­go sub­urb Lin­colnshire, IL, on June 30. The fund’s com­plaint al­leges Emer­gent not on­ly failed to com­plete its fidu­cia­ry du­ties — a com­mon law­suit many com­pa­nies face af­ter a spate of bad news — but al­so en­gaged in in­sid­er trad­ing, with sev­er­al ex­ecs and board mem­bers sell­ing more than $20 mil­lion in stock since April 2020.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.